Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment

@inproceedings{Boyrie2013CystadenocarcinomaOT,
  title={Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment},
  author={Sabrina Boyrie and Isabelle Fauquet and Michel Rives and Caroline G{\'e}n{\'e}b{\`e}s and Jean-Pierre Delord},
  booktitle={SpringerPlus},
  year={2013}
}
BackgroundMutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed.Methods and resultsWe report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation… CONTINUE READING

Figures and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES

Parotid carcinoma: expression of kit protein and epidermal growth factor receptor.

VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

The association of the BRAF(V600e) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis

  • T Kim, P Yj, L Ja
  • Cancer
  • 2012
VIEW 2 EXCERPTS

Mutations of the BRAF gene in human cancer

  • H Davies, B Gr, C Cox
  • Nature
  • 2002
VIEW 1 EXCERPT

Diagnosis and pitfalls in the treatment of parotid tumors.

VIEW 1 EXCERPT